Immunocore Reveals First Data From HIV Infection Candidate Study
Immunocore Holdings plc (NASDAQ:IMCR) has presented the first safety and activity data with IMC-M113V, a bispecific soluble TCR therapy built on…
Gilead Presents Proof-Of-Concept Data For Investigational Combination Regimen Of Lenacapavir With Broadly Neutralizing Antibodies As A Potential Twice-Yearly Approach For The Treatment Of HIV
– Study Demonstrates the Potential of Lenacapavir in Combination with Broadly Neutralizing HIV Antibodies Teropavimab and Zinlirvimab –
– Findings Support Further Evaluation of the Investigational
Co-Diagnostics, Inc. Initiates Clinical Evaluations For Its At-Home And Point-Of-Care Co-Dx PCR Home Platform
Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced
Ovia Health Expands Digital Platform Capabilities To Include Menopause Tracking
Digital platform expansion provides women access to resources for their unique health care needs
Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app,
Eterna Therapeutics Enters Into Option And License Agreement With Lineage Cell Therapeutics To Develop Hypoimmune Pluripotent Cell Lines For Multiple Neurology Indications
Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna"), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with transformational
ProPhase Labs Announces Plans To Initiate Clinical Trial Of Equivir, Goal To Launch Commercially In Q4 2023
ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase"), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), is
Astrazeneca’s Tablet Formulation Of Calquence (Acalabrutinib) Has Been Approved In The European Union (Eu) For Adult Patients With Chronic Lymphocytic Leukemia.
The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the ELEVATE-PLUS trials published in the American Society of
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback
Earlier this week, three bills were introduced and added to the list of measures calling for some sort of psychedelics legalization, while some of the already filed ones continue progressing and others get a thumbs down.
Windtree Therapeutics Has Been Granted U.S. Patent Number 11,583,540 Titled “Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure”
https://ppubs.uspto.gov/pubwebapp/external.html?q=(11583540).pn
Why Chemomab Therapeutics Shares Are Trading Higher Today
Chemomab Therapeutics Ltd (NASDAQ: CMMB) shares are trading higher on Tuesday after the company announced FDA clearance of its Investigational New Drug Application to evaluate CM-101 in a Phase 2 trial in